Physician profile
Millard D Strutin
NPI 1598798654
$578.40
in general payments reported to CMS, 2019-2025
15 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $50.91 · 2021: $61.06 · 2022: $61.63 · 2023: $31.57 · 2024: $49.61 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Polarityte, INC. | $89.12 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $66.68 | 2025 | Dupixent |
| Aerin Medical INC. | $65.18 | 2024-2025 | |
| Shire North American Group INC | $55.09 | 2019 | |
| Neurent Medical Limited | $52.78 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| W. L. Gore & Associates, INC. | $42.79 | 2021-2022 | |
| Ethicon US, LLC | $41.18 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $31.57 | 2023 | Seglentis |
| Indivior INC. | $29.12 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $28.35 | 2021-2022 | |
| Optinose US, INC. | $18.13 | 2024 | |
| Glaxosmithkline, LLC. | $16.65 | 2025 | Nucala |
| Davol INC. | $16.63 | 2019 | |
| Cook Medical LLC | $14.76 | 2019 | |
| Reprise Biomedical, INC. | $10.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millard Strutin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.